Literature DB >> 24232305

Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma.

Mridul Agrawal, Jennifer Kanakry, Christina A Arnold, Daniel L Suzman, Luckson Mathieu, Yvette L Kasamon, Douglas E Gladstone, Richard F Ambinder, Nilanjan Ghosh.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24232305      PMCID： PMC4087073          DOI： 10.1007/s00277-013-1950-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  10 in total

1.  Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.

Authors:  Craig B Reeder; Donna E Reece; Vishal Kukreti; Christine Chen; Suzanne Trudel; Kristina Laumann; Joseph Hentz; Nicholas A Pirooz; Jesus G Piza; Rodger Tiedemann; Joseph R Mikhael; Peter L Bergsagel; Jose F Leis; Rafael Fonseca; Alexander K Stewart
Journal:  Blood       Date:  2010-04-22       Impact factor: 22.113

2.  Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.

Authors:  Patricia M LoRusso; Karthik Venkatakrishnan; Ramesh K Ramanathan; John Sarantopoulos; Daniel Mulkerin; Stephen I Shibata; Anne Hamilton; Afshin Dowlati; Sridhar Mani; Michelle A Rudek; Chris H Takimoto; Rachel Neuwirth; Dixie-Lee Esseltine; Percy Ivy
Journal:  Clin Cancer Res       Date:  2012-03-06       Impact factor: 12.531

3.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

4.  Bortezomib-induced severe hepatitis in multiple myeloma: a case report.

Authors:  Laura Rosiñol; Silvia Montoto; Maria Teresa Cibeira; Joan Bladé
Journal:  Arch Intern Med       Date:  2005-02-28

5.  Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.

Authors:  Vinita Uttamsingh; Chuang Lu; Gerald Miwa; Liang-Shang Gan
Journal:  Drug Metab Dispos       Date:  2005-08-15       Impact factor: 3.922

Review 6.  Cyclophosphamide and cancer: golden anniversary.

Authors:  Ashkan Emadi; Richard J Jones; Robert A Brodsky
Journal:  Nat Rev Clin Oncol       Date:  2009-09-29       Impact factor: 66.675

7.  Anaplastic myeloma with massive extramedullary involvement. Report of two cases.

Authors:  K Foucar; M Raber; E Foucar; B Barlogie; C M Sandler; R Alexanian
Journal:  Cancer       Date:  1983-01-01       Impact factor: 6.860

8.  Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.

Authors:  Donna E Reece; Giovanni Piza Rodriguez; Christine Chen; Suzanne Trudel; Vishal Kukreti; Joseph Mikhael; Mariela Pantoja; Wei Xu; A Keith Stewart
Journal:  J Clin Oncol       Date:  2008-07-21       Impact factor: 44.544

9.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Authors:  Jesús F San Miguel; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; Olga S Samoilova; Anna Dmoszynska; Kudrat M Abdulkadyrov; Rik Schots; Bin Jiang; Maria-Victoria Mateos; Kenneth C Anderson; Dixie L Esseltine; Kevin Liu; Andrew Cakana; Helgi van de Velde; Paul G Richardson
Journal:  N Engl J Med       Date:  2008-08-28       Impact factor: 91.245

10.  Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

Authors:  C B Reeder; D E Reece; V Kukreti; C Chen; S Trudel; J Hentz; B Noble; N A Pirooz; J E Spong; J G Piza; V H J Zepeda; J R Mikhael; J F Leis; P L Bergsagel; R Fonseca; A K Stewart
Journal:  Leukemia       Date:  2009-02-19       Impact factor: 11.528
  10 in total
  6 in total

Review 1.  Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing.

Authors:  Megan J Fitzpatrick; Valentina Nardi; Aliyah R Sohani
Journal:  Skeletal Radiol       Date:  2021-03-09       Impact factor: 2.199

2.  Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy.

Authors:  Wenjiao Tang; Yangfan Xu; Bing Xiang
Journal:  Ann Hematol       Date:  2020-09-02       Impact factor: 3.673

3.  Morphological Transformation of Myeloma Cells into Multilobated Plasma Cell Nuclei within 7 Days in a Case of Secondary Plasma Cell Leukemia That Finally Transformed as Anaplastic Myeloma.

Authors:  Akihito Fujimi; Yasuhiro Nagamachi; Naofumi Yamauchi; Yuji Kanisawa
Journal:  Case Rep Hematol       Date:  2017-12-21

4.  Pleomorphic Multinucleated Plasma Cells Simulating Megakaryocytes in an Anaplastic Variant of Myeloma.

Authors:  Shivangi Harankhedkar; Ruchi Gupta; Khaliqur Rahman
Journal:  Turk J Haematol       Date:  2018-02-06       Impact factor: 1.831

5.  Anaplastic multiple myeloma with MYC rearrangement.

Authors:  Satoshi Ichikawa; Noriko Fukuhara; Ko Hashimoto; Fumiyoshi Fujishima; Ryo Ichinohasama; Hideo Harigae
Journal:  Leuk Res Rep       Date:  2021-12-27

6.  Anaplastic Multiple Myeloma: Case Series and Literature Review.

Authors:  Jian Wu; Emily Chu; Cristiana Costa Chase; Taewoong Choi; Cristina Gasparetto; Ken Young; Yubin Kang
Journal:  Asploro J Biomed Clin Case Rep       Date:  2022-01-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.